Premier online and print content, written by and for #mentalhealth care physicians and professionals. Questions? Email: [email protected].
Cranbury, NJ
Joined February 2009
- Tweets24.4K
- Following5.1K
- Followers112K
- Likes3.5K
🎙️ Episode 2 of The Psych Consult: Second Opinion is here!
Claire Brandon, MD, and endocrinologist Caroline Messer, MD, discuss where thyroid disease and psychiatric illness overlap.
🔗 psychiatrictimes.com/view/po…
🦠 Phase 2 signal-finding trial of bezisterim for the treatment of long COVID shows safety and symptom gains, with strongest benefits for severe fatigue, post-exertional malaise, and cognitive issues. psychiatrictimes.com/view/ne…
How is schizophrenia management evolving? Attend our live national broadcast to explore real-world strategies to manage side effects, support treatment persistence, and optimize long-term functional outcomes in schizophrenia. Register Today! bit.ly/4yjLpCB
🏃 Athletes can feel the relief a substance gives them long before they can see what it costs.
Check out this composite case of cannabis use in a track athlete to learn more about how to assess. psychiatrictimes.com/view/re…
A psychiatric nurse practitioner shares mentorship lessons, training fixes, and practical tips to close prescriber gaps and improve team-based care in this week's episode of "Psyched Perspectives."
psychiatrictimes.com/view/po…
Today marks the first-ever Treatment-Resistant Depression Awareness Day in the US. psychiatrictimes.com/view/th…
Routine symptom measures can sharpen psychiatric diagnosis.
Learn how to gather consistent, evidence-based measurements from the initial evaluation and throughout patient treatment from John Rush, MD, in our October cover: psychiatrictimes.com/view/me…
Mental health care changes lives—and so do the clinicians behind it. 💚🌍
On #WorldMentalHealthDay, we’re reminded that progress in psychiatry means progress for every patient, family, and community. #MentalHealthAwareness #MentalHealth
🚨 The FDA has approved olanzapine (Weltruza) extended-release injectable suspension, a once-monthly subcutaneous long-acting injectable, for adults with schizophrenia. psychiatrictimes.com/view/ol…
Check out the latest episode of "Psychopharm Today"! This month, host Jessica Gannon, MD, interviews Andrew A. Nierenberg, MD, about how a learning health network can transform bipolar disorder care.
Watch it here: psychiatrictimes.com/view/ho…
Listen here: psychiatrictimes.com/view/po…
The October issue of Psychiatric Times is now live! This month, we're rethinking treatment resistance and measurement-based care.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6…
The FDA has cleared Motivista, a prescription digital therapeutic indicated for the negative symptoms of schizophrenia, as an adjunct to outpatient care. This is the first authorized treatment for negative symptoms of schizophrenia in the United States. psychiatrictimes.com/view/fd…
A recent study found that vortioxetine was consistently associated with improvements in depressive symptoms, though improvements in cognitive symptoms were inconsistent, with neutral-to-positive, predominantly domain-specific effects. psychiatrictimes.com/view/vo…
🌴 Join leading psychiatry experts in Aventura, FL, Dec. 4–5 for the 2026 Southern Florida Psychiatry Conference!
Gain practical insights and strategies to enhance patient care.
🔗Register now: hubs.li/Q04zsxqd0
#SoFloPsych #Psychiatry #MentalHealth #CME
Our October theme: PTSD.
If you are interested in being featured in a future Special Report/print issue, submit to our content series! psychiatrictimes.com/view/pr…
Q3 2026 has come to an end. What were the highlights from the psychopharmacology pipeline and FDA this quarter? Find out here: psychiatrictimes.com/view/th…
🍂💊 Check out all the psychopharmacology pipeline & FDA updates from September: psychiatrictimes.com/view/se…
A new cross-sectional study found that 49.0% of US adults who used both alcohol and cannabis in the past month reported using them simultaneously, despite potential compounded risks, including impaired judgment, injury, and intoxication effects. psychiatrictimes.com/view/ho…
Pharmacologic interventions are a critical component of comprehensive suicide prevention. Among currently available interventions, lithium and clozapine have the strongest evidence for reducing suicidal behavior over time: psychiatrictimes.com/view/ev…
Psychiatric Times retweeted
Are we adults at 18?
Courts are repeatedly told by colleagues of mine that people under 25 are impulsive and cannot make decisions for themselves.
The claim is dressed up as neuroscience. What is usually missing is an examination of the actual person. A few years ago I wrote about the same problem with PTSD. This is the next one.
My latest in @PsychTimes:
psychiatrictimes.com/view/ex…
